Edgar Filing: ALLERGAN INC

ALLERGAN, INC.

Date: February 6, 2015

/s/ Matthew J. Maletta

Matthew J. Maletta

Vice President,

Associate General Counsel and Secretary

Form 8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

February 6, 2015 (February 4, 2015)

Date of Report (Date of Earliest Event Reported)

ALLERGAN, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

1-10269

95-1622442

(State of Incorporation)

(Commission File Number)

(IRS Employer

Identification Number)

2525 Dupont Drive

Irvine, California 92612

(Address of Principal Executive Offices) (Zip Code)

(714) 246-4500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

EXPLANATORY NOTE: This Current Report on Form 8-K/A (this “Amendment”) amends certain disclosure made in the Current Report on Form 8-K filed by Allergan, Inc. (“Allergan”) on February 4, 2015 (the “Original Filing”) related to the record date of Allergan’s fourth quarter dividend of $0.05 per share payable on March 20, 2015 to holders of Allergan’s common stock (the “Record Date”). Except for the change of the Record Date, this Amendment does not amend or otherwise update any other information in the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing.

Item 2.02.

Results of Operations and Financial Condition.

On February 6, 2015, the Allergan Board of Directors revised the Record Date from the previously announced date of February 9, 2015 to February 27, 2015.

Item 8.01.

Other Events

The information provided in Item 2.02 is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.